Published in J Neurol on November 01, 1999
D-mannose for the Prevention of UTIs in Multiple Sclerosis | NCT02490046
Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ (2003) 2.29
Characteristics of persons with overactive bladder of presumed neurologic origin: results from the Boston Area Community Health (BACH) survey. Neurourol Urodyn (2012) 1.38
Natural history of multiple sclerosis symptoms. Int J MS Care (2013) 0.93
Constipation in neurological diseases. J Neurol Neurosurg Psychiatry (2003) 0.90
Anorectal dysfunction in multiple sclerosis: a systematic review. ISRN Neurol (2012) 0.89
Prevalence of Sexual Dysfunctions Among Women with Multiple Sclerosis. Sex Disabil (2013) 0.87
Four-year review of sildenafil citrate. Rev Urol (2002) 0.86
Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int (2013) 0.85
Sexual dysfunction in women with multiple sclerosis: Dimensions and contributory factors. J Res Med Sci (2014) 0.83
Monitoring my multiple sclerosis: a patient-administered health-assessment scale. Int J MS Care (2011) 0.82
Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol (2009) 0.82
A longitudinal model for disease progression was developed and applied to multiple sclerosis. J Clin Epidemiol (2015) 0.82
Sacral neuromodulation in patients with multiple sclerosis. World J Urol (2011) 0.81
Urinary dysfunction in women with multiple sclerosis: analysis of 61 patients from rio de janeiro, Brazil. Neurol Int (2013) 0.80
Hospitalization rates and discharge status in multiple sclerosis. Mult Scler Int (2013) 0.80
Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol (2015) 0.79
Autonomic disorders in multiple sclerosis. Autoimmune Dis (2011) 0.78
Advances in the management of neurogenic detrusor overactivity in multiple sclerosis. Int J MS Care (2013) 0.78
Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol (2016) 0.78
Metaboreflex activity in multiple sclerosis patients. Eur J Appl Physiol (2015) 0.77
Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis. Can Urol Assoc J (2014) 0.75
Comparison of Sexual Dysfunction in Women with Migraine and Multiple Sclerosis (MS). Maedica (Buchar) (2016) 0.75
Tablet-based screening improves continence management in multiple sclerosis. Ann Clin Transl Neurol (2015) 0.75
Impact of intermittent catheterization on the quality of life of multiple sclerosis patients. World J Urol (2013) 0.75
Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines. Can Urol Assoc J (2017) 0.75
Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain (1988) 4.69
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet (1989) 4.42
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain (1980) 2.36
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry (1987) 2.33
The prevalence of multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry (1988) 2.20
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet (1989) 1.87
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
B-lymphocyte alloantigens associated with multiple sclerosis. Lancet (1976) 1.73
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology (1998) 1.62
Early maternal and neonatal morbidity associated with operative delivery in second stage of labour: a cohort study. Lancet (2001) 1.61
Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry (1998) 1.60
The British Isles survey of multiple sclerosis in twins. Neurology (1994) 1.57
Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature (1989) 1.49
Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol (2010) 1.49
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry (1987) 1.42
Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain (2000) 1.42
Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain (1996) 1.41
The multiple causes of multiple sclerosis: the importance of age of infections in childhood. J Child Neurol (1987) 1.40
Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimising ascertainment bias. J Med Genet (1989) 1.39
The effect of intravenous aminophylline on essential tremor. Br J Clin Pharmacol (1997) 1.38
Type III collagen mutations in Ehlers Danlos syndrome type IV and other related disorders. Clin Exp Dermatol (1988) 1.38
A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry (1987) 1.35
Multiple sclerosis in the Cambridge health district of east Anglia. J Neurol Neurosurg Psychiatry (1992) 1.33
CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry (2008) 1.32
EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry (1992) 1.29
Cerebellar haemangioblastoma and von Hippel-Lindau disease. Brain (1986) 1.29
Linkage analysis of peripheral neurofibromatosis (Von Recklinghausen disease) and chromosome 19 markers linked to myotonic dystrophy. J Med Genet (1986) 1.26
Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry (2008) 1.24
Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome. Lancet (1978) 1.23
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology (2011) 1.22
The morbidity of multiple sclerosis. Q J Med (1992) 1.21
Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol (1989) 1.20
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology (1995) 1.19
Heat induced aggregation of the sodium dodecyl sulfate-solubilized main intrinsic polypeptide isolated from bovine lens plasma membrane. Biochem Biophys Res Commun (1978) 1.18
Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol (2008) 1.17
The incidence and mortality of multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry (1989) 1.16
Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain (1986) 1.15
The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain (1989) 1.13
Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci (1989) 1.13
Peripheral blood lymphocyte sub-populations and multiple sclerosis. J Neuroimmunol (1984) 1.13
Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry (2008) 1.12
Population based study of late onset cerebellar ataxia in south east Wales. J Neurol Neurosurg Psychiatry (2004) 1.11
HLA and multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry (1987) 1.11
Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology (1999) 1.10
Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain (1996) 1.09
Histocompatibility antigens and post-encephalitic Parkinsonism. J Neurol Neurosurg Psychiatry (1982) 1.08
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol (2008) 1.05
Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Ann Neurol (1994) 1.04
Some properties of lens plasma membrane polypeptides isolated from normal human lenses. Exp Eye Res (1979) 1.03
Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience (1999) 1.00
Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry (2009) 1.00
Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain (1992) 0.99
Cytotoxic and hemolytic effects of Tritrichomonas foetus on mammalian cells. Infect Immun (1990) 0.98
Detection of optic nerve atrophy following a single episode of unilateral optic neuritis by MRI using a fat-saturated short-echo fast FLAIR sequence. Neuroradiology (2001) 0.98
Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet (1984) 0.98
Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol (1989) 0.97
Failure to achieve remyelination of demyelinated rat axons following transplantation of glial cells obtained from the adult human brain. Neuropathol Appl Neurobiol (1996) 0.96
A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. Genes Immun (2010) 0.95
Reversible injury of cultured rat oligodendrocytes by complement. Immunology (1989) 0.95
Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry (1993) 0.95
Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology (1992) 0.94
Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry (1989) 0.94
Microglia-derived IGF-2 prevents TNFalpha induced death of mature oligodendrocytes in vitro. J Neuroimmunol (2002) 0.93
Multiple sclerosis and the HLA-D region: linkage and association studies. J Neuroimmunol (1995) 0.91
The expression of complement regulatory proteins by adult human oligodendrocytes. J Neuroimmunol (1998) 0.90
Oligodendrocyte susceptibility to injury by T-cell perforin. Immunology (1990) 0.90
No association between multiple sclerosis and the Notch3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). J Neurol Neurosurg Psychiatry (2001) 0.90
Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet (1997) 0.90
HLA associations with multiple sclerosis in the Canary Islands. J Neuroimmunol (1998) 0.90
Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther Immunol (1995) 0.89
Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult Scler (2012) 0.88
Cerebrospinal fluid C9 in demyelinating disease. Neurology (1986) 0.88
Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry (2008) 0.88
Analysis of the ion channel complement of the rat oligodendrocyte progenitor in a commonly studied in vitro preparation. Eur J Neurosci (1997) 0.86
Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler (2011) 0.86
Validity of patient-derived disability and clinical data in multiple sclerosis. Mult Scler (2010) 0.86
Oligodendrocyte-macrophage interactions in vitro triggered by specific antibodies. Immunology (1991) 0.86
Suppressor T cells in family members of patients with multiple sclerosis. Brain (1986) 0.86
Multiple sclerosis in the north Cambridgeshire districts of East Anglia. J Neurol Neurosurg Psychiatry (1995) 0.86
Clinical concordance in sibling pairs with multiple sclerosis. Neurology (1996) 0.85
No linkage or association between multiple sclerosis and the myelin basic protein gene in affected sibling pairs. J Neurol Neurosurg Psychiatry (1994) 0.85
Clinical skills evaluation of trainees in a neurology department. Clin Med (2007) 0.85
Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol (2010) 0.85
Subacute sclerosing panencephalitis in Wales. Q J Med (1994) 0.84
A proliferative adult human oligodendrocyte progenitor. Neuroreport (1995) 0.84
T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler (1998) 0.84
Photoproteins as indicators of intracellular free Ca2+. J Biolumin Chemilumin (1989) 0.84
Dentatorubral pallidoluysian atrophy in South Wales. J Neurol Neurosurg Psychiatry (2007) 0.83
Specific induction of intracellular calcium oscillations by complement membrane attack on oligodendroglia. J Neurosci (1993) 0.83
Evidence against linkage of von Recklinghausen neurofibromatosis and chromosome 19 markers. Ann N Y Acad Sci (1986) 0.82
British Isles survey of multiple sclerosis in twins: MRI. J Neurol Neurosurg Psychiatry (1994) 0.82
The pathogenesis of demyelinating disease. Prog Neurobiol (1994) 0.82
Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain (1998) 0.82
Imaging Ca2+ changes in individual oligodendrocytes attacked by T-cell perforin. Immunology (1991) 0.81
Sequence of the human homologue of a mitochondrially encoded murine transplantation antigen in patients with multiple sclerosis. J Neurol (1995) 0.81